[Skip to Content]
[Skip to Content Landing]
April 7, 1989

Mycosis Fungoides

Author Affiliations

THERAKOS West Chester, Pa

THERAKOS West Chester, Pa

JAMA. 1989;261(13):1882. doi:10.1001/jama.1989.03420130044018

To the Editor.—  The report by Drs Weinstock and Horm1 of a significant increase in the incidence of mycosis fungoides over a study period from 1973 through 1984 is of considerable interest. As the authors point out, the etiology of this disease is obscure, but the recent observation of an association between infection by the human T-cell lymphotropic virus type V and disease2 is worth noting. These findings also support the view that a human T-cell lymphotropic virus may be a factor in the etiology.Edelson3 described the relationship between mycosis fungoides and the Sézary syndrome as variants of a T-cell-mediated disease—cutaneous T-cell lymphoma. While Drs Weinstock and Horm1 referred to the poor response to conventional therapy, a new form of therapy named photopheresis (the equipment for which is manufactured by Therakos) has been introduced for the treatment of cutaneous T-cell lymphoma. As originally reported by